Press Releases

Feb 22, 2024

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Read More

Feb 21, 2024

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

Read More

Feb 08, 2024

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Read More

Feb 06, 2024

Veracyte Completes Acquisition of C2i Genomics

Read More

Jan 08, 2024

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform

Read More

Dec 12, 2023

Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Read More

Dec 01, 2023

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Read More

Nov 29, 2023

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

Read More

Nov 22, 2023

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Read More

Nov 07, 2023

Veracyte Announces Third Quarter 2023 Financial Results

Read More